Upcoming Webinar: The Art and Science of Cyclic Peptide Drug Design: From Experimental Dis... Del 27/05/2026 to 27/05/2026 Healthcare Drug discovery Innovative drugs International Digitalization
BCN HEALTH publishes a study evaluating the incidence, management, and associated costs of... 05/05/2026 Healthcare Innovative drugs Personalized medicine Partners - BCN Health
The IIBB-CSIC and Chemotargets promote the development of new therapies against cancer t... 29/04/2026 Healthcare Drug discovery Innovative drugs The agreement combines the preclinical models developed by the Institute of Biomedical Research of Barcelona (IIBB-CSIC)... Partners - Parc Científic de Barcelona
ORYZON to participate in upcoming events in May and June 29/04/2026 Healthcare Drug discovery Innovative drugs Updated data from iadademstat’s clinical trials in acute myeloid leukemia to be presented at EHA-2026 in June. Partners - Oryzon Genomics
I4ID 2026 – 10th Immunotherapies & Innovations for Infectious Diseases Congress Lyon France Del 22/10/2026 to 24/10/2026 Healthcare Innovative drugs
BIOPC 2026 – 11th Bioproduction Congress Lyon France Del 22/09/2026 to 23/09/2026 Healthcare Innovative drugs
AIS 2026 - 14th Antibody Industrial Symposium Montpellier France Del 30/06/2026 to 01/07/2026 Healthcare Innovative drugs
Almirall and Barcelona Supercomputing Center expand their collaboration to accelerate inno... 22/04/2026 Healthcare Access to innovation Innovative drugs The strategic framework agreement deepens the long-standing partnership, leveraging Artificial Intelligence and High... Partners - Almirall
U.S. announces pharmaceutical tariffs under Section 232: what it means for biotech compani... 10/04/2026 Healthcare Drug discovery Rare diseases Innovative drugs Industrial biotechnology International At AseBio, we believe this Executive Order creates uncertainty for the European biotechnology sector—especially for... AseBio
ORYZON strengthens vafidemstat patent portfolio with U.S. Notice of Allowance 25/03/2026 Healthcare Innovative drugs Covers the use of vafidemstat for treating non-aggressive symptoms of Borderline Personality Disorder (BPD). Partners - Oryzon Genomics
